An Exploratory Study of Ranibizumab (Lucentis) for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema Which Has Proven Refractory or Ineligible to Standard Treatment.

Trial Profile

An Exploratory Study of Ranibizumab (Lucentis) for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema Which Has Proven Refractory or Ineligible to Standard Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinal oedema; Uveitis
  • Focus Therapeutic Use
  • Acronyms The LIMO study
  • Most Recent Events

    • 04 Jul 2016 Status changed from recruiting to completed.
    • 15 Apr 2015 According to ClinicalTrials.gov the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2012).
    • 15 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top